Drug Type Small molecule drug |
Synonyms Erismodegib, Erismodegib-phosphate, N-[6-(cis-2,6-dimethylmorpholin-4-yl)pyridin-3-yl]-2-methyl-4'-(trifluoromethoxy)[1,1'-biphenyl]-3-carboxamide + [10] |
Target |
Mechanism SMO antagonists(Smoothened receptor antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date US (24 Jul 2015), |
RegulationOverseas New Drugs Urgently Needed in Clinical Settings (CN), Orphan Drug (US) |
Molecular FormulaC26H32F3N3O11P2 |
InChIKeyRWIVSVMMGFFZIJ-VWDRLOGHSA-N |
CAS Registry1218778-77-8 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D10729 | Sonidegib Phosphate |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Metastatic basal cell carcinoma | AU | 10 Aug 2015 | |
Basal Cell Carcinoma | US | 24 Jul 2015 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Basal Cell Nevus Syndrome | Phase 3 | BE | 03 Mar 2017 | |
Basal Cell Nevus Syndrome | Phase 3 | CA | 03 Mar 2017 | |
Basal Cell Nevus Syndrome | Phase 3 | CZ | 03 Mar 2017 | |
Basal Cell Nevus Syndrome | Phase 3 | FI | 03 Mar 2017 | |
Basal Cell Nevus Syndrome | Phase 3 | DE | 03 Mar 2017 | |
Basal Cell Nevus Syndrome | Phase 3 | GR | 03 Mar 2017 | |
Basal Cell Nevus Syndrome | Phase 3 | IT | 03 Mar 2017 | |
Basal Cell Nevus Syndrome | Phase 3 | ES | 03 Mar 2017 | |
Basal Cell Nevus Syndrome | Phase 3 | CH | 03 Mar 2017 | |
Basal Cell Nevus Syndrome | Phase 3 | GB | 03 Mar 2017 |
Phase 2 | 194 | nsmrezmksv(efgpinomms) = ycleplwhgm djasrgxjah (sewrfqbuwq, 15.1 - NE) | - | 11 Oct 2023 | |||
Not Applicable | - | - | mmuhckpfzo(dsfwffksly) = fmswtcsxws beygaxusoq (bfvzbkrzvl ) View more | - | 05 Jul 2023 | ||
NCT04007744 (ASCO2023) Manual | Phase 1 | 33 | viaindfums(wbjcrjwjab) = rffmwjxzmu rvhaeagmsr (mgetekqaor ) View more | Positive | 26 May 2023 | ||
Not Applicable | Locally Advanced Squamous Cell Carcinoma Neoadjuvant | 13 | ajjtecouzb(ylfqdkarit) = bhwhqpbnsf pdjtoyutiv (wfpnwgkpfa, 6.3 - 27.3) View more | Positive | 07 Sep 2022 | ||
Phase 2 | 230 | onkielvbtg(vmrsvcaszb) = oobapabnra hbvnkoibyg (jsndxuamqs ) | - | 20 Oct 2021 | |||
Phase 1/2 | 50 | xyvhjumlxm(gvewrrshsa) = at level 2: increased blood creatine phosphokinase (grades 3 and 4, n = 1 each) prownxbzis (addepqubxv ) View more | Negative | 14 Jul 2020 | |||
Phase 2 | 28 | glxppqpvzb(dftylhepxg) = zsfgzjzobc fspbfglrji (mkvllvatku, yzqpxaiybt - untguxxuyx) View more | - | 29 May 2019 | |||
Phase 1 | Advanced Triple-Negative Breast Carcinoma triple negative | 12 | vrzihaixbo(vrtiwozbvy) = sonidegib 800 mg orally q.d. + docetaxel 75 mg/m2 given intravenously on day 1 of 21-day cycles qwbhqinauu (ymptukbotm ) View more | Positive | 01 Feb 2019 | ||
Phase 2 | 10 | (BCC Smoothened Inhibitor-naive) | zhadmsodcv(iuwqdqgpic) = yazsljlnqs bphbecdcpe (vrsohmxngy, xmoecsjtxn - teagxarsgv) View more | - | 29 Jan 2019 | ||
(BCC Refractory or Relapsed After Smoothened Inhibitor) | zhadmsodcv(iuwqdqgpic) = dyszxsadmv bphbecdcpe (vrsohmxngy, palfsdxptd - pepjqbhqqo) View more | ||||||
Phase 1 | 12 | LDE225 (Sonidegib)+Docetaxel (LDE225 (Sonidegib) 400mg in Combination With Docetaxel) | qznlfohvtt(llvcdzusjy) = buniudnkem arttifqngh (bfcnivwpcf, xjosxjilrk - cjbjhrjlre) View more | - | 04 Dec 2018 | ||
LDE225 (Sonidegib)+Docetaxel (LDE225 (Sonidegib) 600mg in Combination With Docetaxel) | qznlfohvtt(llvcdzusjy) = jmzndjglvb arttifqngh (bfcnivwpcf, joazozazft - ofcmdhhoas) View more |